Immunity to thrombotic events is achievable if we stop the guessing game: Is this the major hidden message from GRAVITAS?

Thromb Haemost 2011; 106(02): 263-264
DOI: 10.1160/TH11-02-0064

Theme Issue Article

Schattauer GmbH

Autor*innen

Paul A. Gurbel

¹Sinai Center for Thrombosis Research, Baltimore, Maryland, USA
Udaya S. Tantry

¹Sinai Center for Thrombosis Research, Baltimore, Maryland, USA
Kevin P. Bliden

¹Sinai Center for Thrombosis Research, Baltimore, Maryland, USA
Young-Hoon Jeong

¹Sinai Center for Thrombosis Research, Baltimore, Maryland, USA

References
1 Price MJ. The GRAVITAS (Gauging Responsiveness with A VerifyNow as say-Imp act on Thrombosis And Safety) trial. Talk presented at the American Heart Association 2010 Scientific Sessions. November 2010. Chicago, IL, USA.:
2 Gurbel PA, Becker RC, Mann KG. et al. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol 2007; 50: 1822-1834.
3 Wiviott SD, Trenk D, Frelinger AL. et al. PRIN-CIPLE-TIMI 44 Investigators. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 2007; 116: 2923-2932.
4 Gurbel PA, Bliden KP, Butler K. et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 2009; 120: 2577-2585.
5 Gurbel PA, Bliden KP, Butler K. et al. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation 2010; 121: 1188-1199.
6 Bonello L, Tantry US, Marcucci R. et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010; 56: 919-933.